PDA

View Full Version : Entest files another patent application



barbara
03-26-2010, 04:37 PM
Entest BioMedical Files Patent Application On Chemokine Technology To Increase Efficacy Of Tissue-Specific Stem Cell Homing In COPD Treatment
25 Mar 2010


Entest BioMedical Inc. (OTCBB: ENTB) announced the filing of a patent application covering the use of stem cell attracting molecules called chemokines in the treatment of Chronic Obstructive Pulmonary Disease (COPD) as well as other conditions that may benefit from enhanced stem cell homing.

Chemokines are naturally produced by the body in times of tissue injury and are believed to be an essential part of the healing process. Entest's intellectual property utilizes these molecules to attract stem cells to damaged tissue in order to augment efficacy of both existing and newly developed cell therapies.

"Clinical trials of stem cells have demonstrated safety and signs of efficacy in heart failure, liver failure, and peripheral artery disease. Unfortunately there is still much room for improvement in patient outcomes," stated Dr. Steven Josephs, lead inventor of the patent application. "The current invention offers a means of making stem cell therapy work better by increasing the number of stem cells in the tissue where they are needed."

The FDA has previously approved a drug which functions by alteration of stem cell homing. Mozobil, a drug developed by Genzyme Corporation, is used to induce stem cells to leave a specific anatomical location (bone marrow). The methods covered by the Entest patent application function in an opposite manner by utilizing specific molecules to attract stem cells.

"Today's patent filing represents Entest's global strategy of addressing COPD through a multi-disciplinary manner," said David Koos, Chairman and CEO of Entest. "Since some of these technologies may be useful in augmentation of stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas."

Source
Entest BioMedical Inc.